Irisin Levels in Patients With Charcot-Marie-Tooth (CMT) Disease

CompletedOBSERVATIONAL
Enrollment

20

Participants

Timeline

Start Date

November 2, 2019

Primary Completion Date

October 31, 2020

Study Completion Date

December 30, 2020

Conditions
Charcot-Marie-Tooth Disease
Interventions
DIAGNOSTIC_TEST

Bioimpedenziometry, Handgrip strenght evaluation

The measurement of body composition was performed using Bioimpedance (BIA 101, Akern srl, Pontassieve (FI), Italy). The handgrip dynamometer (Jamar, Sammons Preston, Bolingbrook, IL, USA) was used to determine the isometric force of the forearm.

DIAGNOSTIC_TEST

Evaluation on blood specimens

Serum samples were assayed for calcium, phosphorus, magnesium, iron, lactate dehydrogenase (Ldh), creatine phosphokinase (Cpk), creatine kinase myocardial band (Ckmmb), myoglobin, thyroid stimulating hormone (TSH), 25(OH)-Vitamin D, osteocalcin, bone alkaline phosphatase (b-ALP), C-terminal telopeptide of type I collagen (CTX-I), haptoglobin, sclerostin, myostatin, and Irisin. Irisin serum concentrations were detected using a competitive ELISA kit (AdipoGen, Liestal, Switzerland)

Trial Locations (1)

70124

Policlinic Hospital, Bari

All Listed Sponsors
lead

University of Bari

OTHER

NCT04786522 - Irisin Levels in Patients With Charcot-Marie-Tooth (CMT) Disease | Biotech Hunter | Biotech Hunter